Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2017
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
- 19 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 04 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrial.gov record.